Todas las noticias

26 SEPT 2026

SFNCL 2026

Spineway Group se complace en anunciar su participación en el congreso anual de la Sociedad Francesa de Neurocirugía Privada (SFNCL), que se celebrará el 26 de septiembre de 2026 en Marsella.

Eventos
25 ENE al 28 ENE 2027

WHX Dubai 2027

Spineway Group participará en WHX Dubai 2027, uno de los mayores eventos internacionales del sector sanitario, que se celebrará en el Dubai Exhibition Centre, Expo City.

Eventos
30 JUL 2026

H1 2026 results

Continued growth - Stable results - Strong embedded growth drivers - Issuance of straight bonds to finance future growth

Comunicados de prensa
04 JUN 2026

SPINEWAY to participate in the SFCR Annual Congress

SPINEWAY, a specialist in innovative implants for the treatment of severe spine disorders, is once again participating in the 2026 Annual Congress of the French Spine Surgery Society (SFCR), to be held from June 11 to 13 at the Palais du Pharo in Marseille.

Comunicados de prensa
30 ABR 2026

First-quarter 2026 revenue

High order volume / Slower-than-expected normalization of supply chains / 2026: growth trajectory confirmed

Comunicados de prensa
07 ABR 2026

Minutes of the General Meeting of April 2, 2026

The Combined General Meeting (Ordinary and Extraordinary) of Spineway shareholders was held on first notice on Thursday 2 April 2026 at 10.00 am at the company’s registered office, 7 allée Moulin Berger in Ecully (69).

Comunicados de prensa
26 MAR 2026

Webinaire Spineway sur les résultats annuels 2025 et les perspectives

Le groupe Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), a organisé jeudi 19 mars un webinaire au cours duquel, Stéphane Le Roux, PDG de Spineway, et Erwan Martin, Directeur financier, ont présenté les résultats annuels 2025 et les perspectives du Groupe.

Comunicados de prensa
17 FEB 2026

2025 annual results

• Revenue up 4% • Improved results • Stronger growth potential

Comunicados de prensa
13 ENE 2026

2025 revenue of €12.4 million, with an acceleration of sales in Q4 2025 (+34%)

In the final quarter of 2025, Spineway, a specialist in innovative implants for the treatment of severe spine disorders, benefited from an acceleration in sales across all of its markets and the receipt of key account orders deferred from the first half of the year. With revenue of €3.8 million, up 34% compared with Q4 2024 (€2.8 million), Spineway recorded a particularly dynamic fourth quarter.

Comunicados de prensa
CARGANDO